Where to begin?
In August 2026, the innovative drug sector remains highly active. Recently, Genhouse Pharma (Suzhou) Co., Ltd. (Genhouse Pharma) submitted a listing application to the main board of the Hong Kong Stock Exchange, with Huatai International as its sole sponsor. This marks the company's second attempt to enter the Hong Kong stock market, following its initial filing in January 2026.
As a 18A biotech firm, its core product, GH31, has received substantial financial backing from a multinational pharmaceutical company. The company's pipeline focuses on the "undruggable" RAS pathway and the blue ocean "synthetic lethality" space, highlighting its unique value. However, its most advanced asset is still in Phase II clinical trials, and the lack of clear efficacy results presents a significant risk factor.
Short-term profitability driven by licensing revenue, R&D spending continues to rise
From a financial perspective, Genhouse Pharma currently has no revenue from commercialized products, with income primarily sourced from out-licensing collaborations. For the fiscal years 2024, 2025, and the five months ended May 31, 2026, the company reported revenues of approximately RMB 4.69 million, RMB 1.27 million, and RMB 558 million, respectively. The significant revenue jump in the first five months of 2026 was mainly due to an exclusive out-licensing agreement with Gilead Sciences for the GH31 program, which included an upfront, non-refundable payment of $80 million (pre-tax, approximately RMB 557.4 million).
Gross profit trends mirrored revenue changes. Gross profit was approximately RMB 2.31 million in 2024, falling to about RMB 150,000 in 2025, before surging to RMB 556 million in the first five months of 2026, again primarily driven by the Gilead licensing upfront payment. On the profit side, the company recorded a net loss of RMB 152 million in 2024, which narrowed to RMB 144 million in 2025. For the first five months of 2026, thanks to the large upfront payment, the company achieved a net profit of RMB 355 million, marking a significant turnaround from a loss. However, it is noteworthy that administrative expenses during the same period were as high as RMB 73.192 million, far exceeding the full-year figures of RMB 23.596 million in 2024 and RMB 29.292 million in 2025, primarily due to share-based compensation and financing-related costs.
In terms of R&D, spending was RMB 103 million in 2024, RMB 79.196 million in 2025, and RMB 37.758 million in the first five months of 2026, a 35.5% increase from the same period last year. The company also warned that as clinical trials progress, future R&D expenditures will increase significantly, with the average cash burn rate expected to reach 4.3 times the 2025 level.
Regarding cash flow, net cash used in operating activities was RMB 107 million in 2024 and RMB 81.66 million in 2025, which turned into a net inflow of RMB 420 million in the first five months of 2026 due to the upfront payment. As of the end of June 2026, the company held approximately RMB 344 million in cash and cash equivalents, RMB 301 million in financial assets at fair value through profit or loss, and interest-bearing bank borrowings of about RMB 47.798 million. Debt and financing pressures are also significant. As of May 31, 2026, the company's net liabilities were RMB 379 million, current liabilities net amounted to RMB 412 million, and equity share redemption liabilities were about RMB 996 million. Early-stage share repurchase agreements stipulate that if a qualified IPO is not completed by December 31, 2027, investors have the right to demand share redemption at principal plus 8% annual interest, adding time pressure to the company's listing process.
Pipeline centered on the RAS pathway and synthetic lethality
Founded in May 2014, Genhouse Pharma is a biopharmaceutical company focusing on targeted therapies in oncology. Its core pipeline of independently developed innovative drug candidates revolves around the RAS signaling pathway and synthetic lethality mechanisms. The company's pipeline includes eight drug candidates, with four in clinical stages, one (GH31) having received IND approval from both China's NMPA and the US FDA, and three in preclinical stages. Among them, the core assets GH21 and GH31 form the two pillars of the company's valuation.
RAS pathway: Tackling the "undruggable" target, GH21 is globally advanced
The RAS gene is a key regulatory switch for human cell growth. Once mutated, cells continuously proliferate, ultimately leading to tumors. However, due to its smooth protein surface and lack of drug binding sites, RAS has long been considered an "undruggable" target. According to CIC data, approximately 19.0% of global solid tumors in 2025 were associated with RAS mutations, with KRAS mutations accounting for 90% of all RAS mutations, making it the primary oncogenic driver. Several KRAS G12C inhibitors have been approved globally, but there remains a significant unmet need in the broader RAS pathway inhibition space.
Genhouse Pharma's RAS signaling pathway pipeline is represented by GH21, GH55, and the preclinical candidate GH58. GH21 is an allosteric SHP2 inhibitor, ranking second globally in clinical progress, and is currently in Phase II trials primarily for KRAS G12C mutant solid tumors and third-generation EGFR-TKI resistant non-small cell lung cancer. SHP2, as a key node connecting upstream RTK signaling to the RAS pathway, has no approved drugs globally, presenting vast potential but also high development difficulty. GH21's design highlight is its allosteric inhibition mechanism, which avoids the off-target effects and poor membrane permeability issues of traditional active site inhibitors by binding and stabilizing SHP2 in its inactive conformation. Preclinical studies show GH21 has limited off-target effects on non-targets and possesses good metabolic properties and oral bioavailability.
In a single-agent Phase I trial, GH21 demonstrated initial efficacy signals: a disease control rate (DCR) of 60% (6/10) in NSCLC patients with KRAS G12C mutations, 57% (4/7) in NSCLC patients with EGFR mutations/high expression, 100% (4/4) in head and neck squamous cell carcinoma patients, and 75% (3/4) in esophageal cancer patients. Safety data indicated GH21 was well-tolerated. However, as Phase I trials primarily focus on safety exploration, this data is insufficient to confirm efficacy, and the company's R&D focus has shifted to combination therapies.
According to CIC data, GH21 can be combined with various drugs like KRAS inhibitors, MEK inhibitors, EGFR-TKIs, and PD-1 inhibitors, covering multiple indications including NSCLC, colorectal cancer, and pancreatic cancer. The company is currently conducting a Phase 1b/2 trial in China (in combination with goserelin developed by Chia Tai Tianqing) and a Phase II trial (for patients resistant to KRAS G12C inhibitors), along with a Phase 1b/2 trial exploring a combination with osimertinib (supplied by AstraZeneca). However, no key data readouts are available from these trials: the Phase II trial for resistant patients has only enrolled 5 patients, and the osimertinib combination trial has enrolled 36 patients, with no interim analysis results. The company plans to complete the Phase II trial for resistant patients in the fourth quarter of 2027 and submit a conditional NDA in 2028, but there is significant uncertainty about whether these timelines will be met. Notably, the NMPA has strict standards for conditional approval, requiring drugs to treat serious, life-threatening diseases with no effective treatment and demonstrating efficacy and clinical value. It remains unclear whether GH21 can meet these requirements. Even if conditional approval is granted, the company must complete confirmatory clinical trials; failure to prove clinical benefit could lead to the risk of marketing authorization withdrawal.
For commercialization, the exclusive global rights (excluding Mainland China, Hong Kong, Macau, and Taiwan) for the development and commercialization of GH21 have been licensed to HUYABIO International, with a potential total transaction value of up to approximately $282 million. In other RAS pathway developments, GH55 is a dual-mechanism ERK1/2 inhibitor currently in a Phase I monotherapy trial in China, expected to be completed in the fourth quarter of 2026. No ERK inhibitors have been approved globally, and GH55 is the second fastest-progressing ERK inhibitor candidate in clinical development in China. GH21 and GH55, respectively regulating upstream and downstream RAS signaling, have shown synergistic effects in preclinical studies, and the company has received IND approval for the combination therapy, with the first patient enrolled in March 2026. GH58 is a PAN-RAS inhibitor in the preclinical stage, with an IND application planned for 2028.
In terms of market landscape, although no SHP2-targeting drugs have been approved, competition is intense. Novartis' TNO-155, the first highly selective allosteric SHP2 inhibitor to enter clinical trials globally, has advanced to Phase II in multiple indications. In China, JAB-3312 combination therapy has entered Phase III registrational clinical trials, making it the first SHP2 inhibitor globally to reach this stage. Previously, Tianfeng Securities estimated it could be approved in China in 2026. However, SHP2 inhibitor development is not without challenges: JAB-3068, another allosteric SHP2 inhibitor, progressed to Phase II but was discontinued in 2023; Revolution's RMC-4630 was returned by Sanofi, and its combination therapies with KRAS G12C inhibitor Lumakras and MEK inhibitor cobimetinib did not achieve ideal results. Furthermore, because SHP2 is not a tumor driver itself, monotherapy activity is limited (e.g., Novartis' TNO-155 had a 0% objective response rate in Phase I), leading the industry to focus almost entirely on combination therapies. With a competitor targeting the same target already in Phase III, GH21, despite being second globally in clinical progress, does not have a significant advantage, and the market landscape remains highly uncertain.
Synthetic lethality: A blue ocean with vast potential, GH31 backed by Gilead
The mechanism of synthetic lethality is straightforward: cells can survive with the inactivation of either of two genes, but simultaneous inactivation leads to cell death. Tumor cells naturally have a deficiency in one gene pathway, and synthetic lethality therapies aim to precisely block the alternative pathway they depend on, selectively killing tumor cells while sparing normal cells. Although there are many promising targets in this field, only PARP inhibitors have been successfully approved in over a decade, and the PARP space is already crowded, with seven products approved globally. Genhouse Pharma has positioned several drug candidates in the synthetic lethality direction: GH31 (MAT2A inhibitor, with IND approval in China and the US), GH56 (MTA-cooperative PRMT5 inhibitor, Phase I), GH2616 (KIF18A inhibitor, Phase I), and two preclinical candidates. GH31 and GH56 target the MTAP-deficient synthetic lethality axis. According to CIC data, MTAP deficiency is present in about 15% of solid tumors, with higher prevalence in glioblastoma (58%), pancreatic cancer (40%), and adult T-cell leukemia (14%), and around 2% in colorectal cancer, representing significant market potential.
In terms of development progress, GH2616 is the third KIF18A inhibitor globally to enter clinical trials. For the MAT2A target that GH31 targets, existing clinical data is still limited. A domestic competitor, ISM3412, completed its first patient dosing in Phase I in June 2025, progressing slightly faster than Genhouse Pharma. However, GH31 has successfully been licensed to Gilead, securing an $80 million upfront payment and up to $1.45 billion in milestone payments, which to some extent validates the target's value. The company's future R&D focus in the synthetic lethality field may shift to GH56 and GH2616, with Phase I trials for both drugs expected to be completed in the second or third quarter of 2027.
Summary
Overall, Genhouse Pharma's R&D pipeline offers differentiated, rare value—one aspect is the long-considered "undruggable" RAS-MAPK pathway, and the other is the synthetic lethality frontier, still a blue ocean market. Both are at the core of current global innovative drug trends. The core product, GH31, has received backing from Gilead, and GH21 is in the top tier of global clinical progress, giving the company more potential than typical 18A biotech firms. However, investors must also carefully assess the associated risks. The R&D in the RAS pathway and synthetic lethality fields carries high uncertainty, and the most advanced asset is only at Phase II, far from commercialization, making it difficult to change the continuous loss situation in the short term. Coupled with the listing time pressure from the share repurchase agreement, the intense competitive landscape for the SHP2 target, and the uncertainty of regulatory approval, whether the company can realize its pipeline value as scheduled still requires time and data to verify.
Comments